3 results about "Lung tuberculosis" patented technology

The application discloses an aptamer-nano gold test strip for screening human pulmonary tuberculosis and an application thereof, and belongs to the technical field of biological detection. The application successfully constructs an aptamer-nano gold test strip for screening human pulmonary tuberculosis, realizes rapid detection of a pulmonary tuberculosis marker ESAT-6 antigen, adopts mercapto-modified aptamer to modify nano gold to form stable gold label probes, adopts a mixed solution composed of a biotin-modified aptamer solution and a streptavidin solution, and constructs an ESAT-6 antigen test strip by using an ESAT-6 antigen solution. The constructed test strip has good sensitivity in ESAT-6 antigen detection, has good detection effect in the antigen concentration range of 100 pg / mL-500 pg / mL, and has good specificity, stability, repeatability and accuracy.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The application discloses a kind of drug combination and its application.The application provides a kind of drug combination or pharmaceutical composition, the active component of the drug combination or pharmaceutical composition includes material A, material B, material C and material D;Material A is compound I or its pharmaceutically acceptable salt;Material B is isoniazid (H) or its pharmaceutically acceptable salt;Material C is rifampicin (R) or its pharmaceutically acceptable salt;Material D is pyrazinamide (Z) or its pharmaceutically acceptable salt.The drug combination or pharmaceutical composition of the application can reduce alveolar inflammation, pulmonary tuberculosis inflammatory lung injury and pulmonary tuberculosis secondary fibrosis, while increasing the penetration of anti-tuberculosis drugs in the lesion site, to accelerate the treatment response, reduce the risk of recurrence.